Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. "We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame. Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine because of the use of GSK's boosting adjuvant, are to start in September. Trials of the mRNA vaccine candidate should begin around the end of the year, the company said. In April, Sanofi said it had manufacturing capacity for 600 million doses for its recombinant vaccine, with the ambition to double production by mid-2021.

Source: bd News24 June 23, 2020 04:52 UTC